Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 10/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86695 | 0.86 | CA1 (0.49) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL13384649 | 0.84 | CA1 (0.47) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL19860674 | 0.84 | CA1 (0.47) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL4932070 | 0.81 | CA1 (0.51) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL4932075 | 0.81 | CA1 (0.51) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL12274268 | 0.81 | CA1 (0.51) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL29455726 | 0.81 | CA1 (0.51) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL19357503 | 0.81 | CA2 (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL21224562 | 0.81 | CA2 (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL9281071 | 0.81 | CA1 (0.55) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CA1 4007/4885CA2 4649/4885CA7 4482/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | CA1 4007/4885CA2 4649/4885CA7 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.